Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-000853-29
    Sponsor's Protocol Code Number:TRACE
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2020-10-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2018-000853-29
    A.3Full title of the trial
    Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial
    Trattamento di infezioni virali chemio-refrattarie dopo trapianto allogenico di cellule staminali con cellule T multispecifiche contro CMV, EBV e AdV: una sperimentazione clinica di fase III, prospettica, multicentrica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Treatment of viral infections after stem cell Transplantation with specific immune cells
    Trattamento delle infezioni virali dopo trapianto di cellule staminali con specifici cellule immunitarie
    A.3.2Name or abbreviated title of the trial where available
    Multivirus-specific T-cell transfer post SCT vs AdV, CMV and EBV infections (TRACE)
    TRACE
    A.4.1Sponsor's protocol code numberTRACE
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorKLINIKUM DER UNIVERSITAET MUENCHEN
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationKlinikum der Universität München - Dr. von Hauner Children's Hospital
    B.5.2Functional name of contact pointPed. Hematology/Oncology, TRACE
    B.5.3 Address:
    B.5.3.1Street AddressLindwurmstrasse 4
    B.5.3.2Town/ cityMunich
    B.5.3.3Post code80337
    B.5.3.4CountryGermany
    B.5.6E-mailonkostudien.hauner@med.uni-muenchen.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/15/1438 (AdV), 1439 (CMV) and 1440 (EBV)
    D.3 Description of the IMP
    D.3.1Product nameMultivirus (CMV, EBV, AdV-) specific T cells
    D.3.2Product code [Multivirus (CMV, EBV, AdV-) specific T cells]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMultivirus (CMV, EBV, AdV-) specific T cells
    D.3.9.2Current sponsor codeAllogeneic human multivirus specific T cells enriched for specificity against CMV, EBV, AdV
    D.3.9.3Other descriptive nameAllogeneic human multivirus specific T cells enriched for specificity against CMV, EBV, AdV
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number1000 to 20000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product Yes
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberEMA/277503/2013
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeHuman multivirus-specific T cells enriched for specificity against Cytomegalovirus, Adenovirus and Epstein-Barr Virus
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation
    Infezioni chemio-refrattarie di AdV, CMV ed EBV dopo trapianto di cellule staminali allogeniche
    E.1.1.1Medical condition in easily understood language
    infections with the viruses AdV, CMV and EBV which occur after stem cell transplantation and could not be successfully treated with available chemotherapy
    infezioni con virus AdV, CMV ed EBV che si verificano dopo trapianto con cellule staminali e che non hanno potuto essere trattate con successo con le chemioterapia disponibile
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10047465
    E.1.2Term Viral infections NEC
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluation of efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation
    Valutazione dell’efficacia del trasferimento di cellule T multi-specifiche in pazienti con infezioni virali chemio-refrattarie dopo il trapianto allogenico di cellule staminali
    E.2.2Secondary objectives of the trial
    - Incidence and severity of newly occurring GvHD
    - Incidence and severity of acute toxicity
    - Effect on viral load of underlying viral infection
    - Clinical response/resolution of symptoms of underlying viral infection
    - Overall survival
    - Necessity and duration of antiviral chemotherapy
    - Incidence of viral infections other than underlying viral infection:
    evaluation of putative prophylactic effect of treatment
    - Days of hospitalization
    - Quality of life
    - Effect on the patients' T-cell immunity in vivo
    - Quality of the IMP and performance of the CliniMACS® Prodigy
    - Evaluation of the drop-out rate
    - Evaluation of time from inclusion to administration of the IMP
    - Overall safety evaluation
    - Concomitant medication
    Incidenza e gravità di GvHD di nuova comparsa
    Incidenza e gravità della tossicità acuta
    Effetto sulla carica virale dell’infezione virale sottostante
    Risposta/risoluzione clinica dei sintomi dell’infezione virale sottostante
    Sopravvivenza complessiva
    Necessità e durata della chemioterapia antivirale
    Incidenza delle infezioni virali diverse da quella sottostante: valutazione del presunto effetto profilattico del trattamento
    Giorni di ricovero
    Qualità della vita
    Effetto sull’immunità del paziente alle cellule T in vivo
    Qualità dell’IMP e prestazioni di CliniMACS® Prodigy
    Valutazione del tasso di abbandoni
    Valutazione del tempo intercorso fra inclusione e somministrazione dell’IMP
    Valutazione complessiva sulla sicurezza
    Farmaci concomitanti
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adult or paediatric patients (>2 months of age) after HSCT suffering from new or reactivated CMV, EBV or AdV infection and refractory to standard antiviral treatment for two weeks (defined as =1 log decrease in viral load over two weeks) as confirmed by quantitative blood PCR analysis
    2. Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory infection
    3. Written informed consent given (patient or legal representative)
    1. Pazienti adulti o pediatrici (oltre 2 mesi di età) post HSCT, affetti da infezione da CMV, EBV o AdV, nuova o riattivata, refrattari ai trattamenti antivirali standard per due settimane (definiti come =1 riduzione logaritmica registrata della carica virale nel corso di due settimane), confermati da un’analisi PCR quantitativa del sangue
    2. Donatori HSCT originali disponibili con una risposta immunitaria almeno al virus che causa l’infezione refrattaria alla terapia
    3. Concessione del consenso informato scritto (paziente o legale rappresentante)
    E.4Principal exclusion criteria
    1. Acute GvHD > grade II or extensive chronic GvHD at time of T-cell transfer
    2. Treatment with steroids (>1 mg/kg Prednisone equivalent) at Screening
    3. Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. In case of T-cell depleted HSCT, a prescheduled prophylactic DLI =3 x 10e5 T cells/kg BW is not
    considered an exclusion criteria.
    4. Organ dysfunction or failure as determined by Karnofsky (age >16 years) or Lansky (age =16 years) score =30%
    5. Concomitant enrolment in another clinical trial interfering with the endpoints of this study
    6. Any medical condition which could compromise participation in the study according to the investigator's assessment
    7. Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study
    8. Second line or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab from Screening until 8 weeks after IMP infusion
    9. Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test.
    10. Female patient who is pregnant or breast-feeding, or adult of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8) Note:
    women of childbearing potential must have a negative serum pregnancy test at study entry
    11. Known hypersensitivity to iron dextran
    12. Patients unwilling or unable to comply with the protocol or unable to give informed consent.
    1. GvHD acuto di grado superiore a II oppure GvHD esteso cronico al momento del trasferimento di cellule T
    2. Trattamento con steroidi (>1 mg/kg di Prednisone equivalente) allo screening
    3. Infusione di linfociti del donatore (DLI) terapeutica da 4 settimane prima all’infusione dell’IMP a 8 settimane dopo l’infusione dell’IMP. In caso di HSCT impoverito di cellule T, una DLI profilattica precedentemente prevista =3 x 105 cellule T/kg di peso corporeo non è considerato un criterio di esclusione.
    4. Disfunzione o malattia organica determinata secondo Karnofsky (età superiore ai 16 anni) o secondo Lansky (età minore o uguale ai 16 anni) con un punteggio =30%
    5. Arruolamento concomitante in un altro studio clinico che interferisca con i risultati di questo studio
    6. Qualunque condizione medica che possa compromettere la partecipazione allo studio secondo la valutazione dello sperimentatore
    7. Progressione di una malattia sottostante (malattia che ha portato all'indicazione di trapianto di cellule staminali ematopoietiche (HSCT) per es. leucemia) che possa limitare l’aspettativa di vita al di sotto della durata dello studio
    8. Trattamento antivirale di seconda linea o sperimentale diverso da Ganciclovir/Valganciclovir, Foscarnet, Cidofovir e Rituximab dallo screening fino a 8 settimane dopo l’infusione dell’IMP
    9. Infezione HIV nota. Nel caso in cui i pazienti non dispongano di un test HIV negativo effettuato entro 6 mesi prima dell’arruolamento nello studio, la negatività all’HIV dovrà essere confermata da un test di laboratorio con esito negativo.
    10. Pazienti donne in gravidanza o in allattamento al seno o adulte e potenzialmente fertili che non siano disposte a utilizzare un metodo efficace di controllo delle nascite dallo screening fino all’ultima visita di follow-up (FU6, Visita 8) Nota: le donne potenzialmente fertili devono risultare negative a un test di gravidanza sul siero al momento dell’inclusione nello studio
    11. Nota ipersensibilità al ferro destrano
    12. Pazienti non disposti o non in grado di rispettare il protocollo o non in grado di fornire un consenso informato.
    E.5 End points
    E.5.1Primary end point(s)
    - Percentage of patients with viral clearance (defined as two consecutive negative PCRs)
    - Percentage of patients with progression between Day 7 and Week 8 after T-cell transfer
    Percentuale di pazienti con scomparsa del virus (definiti come due PCR negative consecutive)
    Percentuale di pazienti con progressione fra il Giorno 7 e la Settimana 8 dopo il trasferimento di cellule T
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 8 and Week 15
    Week 8 and Week 15
    E.5.2Secondary end point(s)
    - Incidence/severity of acute GvHD = grade II until Week 8 and Week 15.
    - Incidence of newly occurring acute GvHD grade I from Day 0 to Week 8 and Week 15.
    - Incidence of chronic GvHD from Day 7 to Week 8 and to Week 15 after T-cell transfer.
    - Time to newly occurring acute and chronic GvHD.
    - Acute toxicity: maximum toxicity on the day of T-cell transfer evaluated by measuring vital signs prior to and at different times after the T-cell transfer and monitoring of specific adverse events (chills, nausea, vomiting, diarrhoea, abdominal pain, allergic reactions, respiratory dysfunction or headache from 1 hour prior to T-cell transfer to 4 hours post infusion).
    - Change in viral load of underlying viral infection as assessed by quantitative PCR analysis of peripheral blood; samples taken weekly from Day 7 to Week 8 after T-cell transfer as compared to samples taken
    at Day 0.
    - Time to 1 log change in viral load.
    - Percentage of patients with =1 log decrease in CMV, EBV or AdV viral load at Week 8.
    - Number of reactivations of the underlying viral infection following initial viral clearance until end of follow-up.
    - Number of patients with reduction or clearance of clinical symptoms of underlying viral infection from Day 7 to Week 8 after T-cell transfer as compared to Day 0.
    - Overall survival rate (OS): From Day 0 to end of follow-up.
    - Number of days requiring antiviral chemotherapy after T-cell transfer from Day 7 to Week 8 after T-cell transfer.
    - Time to last administration of defined antiviral medication or switch to prophylactic treatment from Day 0 to Week 8 after T-cell transfer.
    - Number of new viral reactivations (CMV, AdV or EBV) other than the underlying viral infection per patient as assessed by PCR analysis and clinical symptoms throughout the study.
    - Number of days hospitalized after T-cell transfer from Day 7 to Week 8.
    - EQ-5D and FACT-BMT for adult patients (=18 years), and PEDS-QL for paediatric patients (<18 years) at Screening and Week 8.
    - T-cell phenotyping, samples taken at Screening, Day 0 and each visit from Day 7 to Week 15 after T-cell transfer. Analysis of virus-specific T cells: number of in vivo expanded virus specific T cells in peripheral blood samples taken at Screening, Day 0, Day 7 to Week 15 after T-cell transfer.
    - Assessment of the number and viability of CD3+ cells and percentage of IFN-gamma+ cells and cellular composition in the IMP.
    - Drop-out rate at Day 0 and reasons for drop-out.
    - Number of days from Screening to Day 0 (day of T-cell transfer).
    - Documentation of incidence, severity and type of adverse events from Day 0 to Week 8 and serious adverse events throughout the study.
    - Physical examination and vital signs from Screening to Week 8; Karnofsky/Lansky index will be assessed at Screening and at Week 8.
    - Laboratory values for clinical chemistry and haematology from Screening to Week 8.
    - Documentation of all concomitant medication from Screening to Week 8.
    - During follow-up Week 15, only antiviral therapy, immunosuppression and SAE-related concomitant medication as well as chemotherapy will be documented.
    - Non-therapeutic DLI has to be documented as concomitant medication (definition see exclusion criteria).
    - Treatment with multivirus-specific T cells after Week 8 will also be documented as concomitant medication.
    Incidenza/gravità di GvHD acuta di grado superiore a II fino alla Settimana 8 e Settimana 15.
    Incidenza di GvHD acuta di nuova comparsa di grado I dal Giorno 0 fino alla Settimana 8 e Settimana 15.
    Incidenza di GvHD cronica dal Giorno 7 alla Settimana 8 e alla Settimana 15 dopo il trasferimento di cellule T.
    Tempo fino comparsa di GvHD acuta e cronica di nuova comparsa.
    Tossicità acuta: massima tossicità il giorno del trasferimento di cellule T valutata misurando i segni vitali prima e in diversi momenti dopo il trasferimento di cellule T e monitorando gli eventi avversi (brividi, nausea, vomito, diarrea, dolore addominale, reazioni allergiche, disfunzioni respiratorie o mal di testa da 1 ora prima del trasferimento delle cellule T fino a 4 ore dopo l’infusione).
    Cambiamento nella carica virale dell’infezione virale sottostante valutato tramite analisi PCR del sangue periferico; campioni prelevati settimanalmente dal Giorno 7 alla Settimana 8 dopo il trasferimento di cellule T confrontati con campioni prelevati il Giorno 0.
    Tempo necessario per 1 variazione logaritmica della carica virale.
    Percentuale di pazienti con un decremento logaritmico =1 nella carica virale CMV, EBV o AdV alla Settimana 8.
    Numero di riattivazioni dell’infezione viralesottostante dopo la scomparsa iniziale di virus fino alla fine del follow-up.
    Numero di pazienti con riduzione o scomparsa di sintomi clinici dell’infezione virale sottostante dal Giorno 7 alla Settimana 8 dopo il trasferimento di cellule T rispetto al Giorno 0.
    Tasso di sopravvivenza complessiva (OS): Dal Giorno 0 alla fine del follow-up.
    Numero di giorni per cui è richiesta la chemioterapia antivirale dopo il trasferimento di cellule T dal Giorno 7 alla settimana 8 dopo il trasferimento di cellule T.
    Tempo fino all’ultima somministrazione del farmaco antivirale definito o del passaggio al trattamento profilattico dal Giorno 0 alla Settimana 8 dopo il trasferimento di cellule T.
    Numero di nuove riattivazioni virali (CMV, AdV o EBV) diverse dall’infezione virale sottostante per paziente, per come valutata dall’analisi PCR e dai sintomi clinici nel corso dello studio.
    Numero di giorni di ricovero dopo il trasferimento di cellule T dal Giorno 7 alla Settimana 8.
    Qualità della vita
    EQ-5D e FACT-BMT per pazienti adulti (=18 anni) e PEDS-QL per pazienti pediatrici (<18 anni) allo screening e alla Settimana 8.
    Fenotipizzazione delle cellule T, campioni prelevati allo screening, al Giorno 0 e ad ogni visita dal Giorno 7 alla Settimana 15 dopo il trasferimento di cellule T.
    Analisi di cellule T specifiche per virus: numero di cellule T specifiche per virus espanse in vivo in campioni di sangue periferico prelevati allo screening, al Giorno 0, dal Giorno 7 alla Settimana 15 dopo il trasferimento di cellule T.
    Valutazione del numero e dell’idoneità delle cellule CD3+ e percentuale di cellule IFN-gamma+ e composizione cellulare nell’IMP.
    Tasso di abbandoni al Giorno 0 e motivi dell’abbandono.
    Numero di giorni dallo Screening al Giorno 0 (giorno del trasferimento di cellule T).
    Documentazione di incidenza, gravità e tipo di eventi avversi dal Giorno 0 alla Settimana 8 e di gravi eventi avversi durante tutto lo studio.
    Esame fisico e segni vitali dallo Screening alla Settimana 8; l’indice di Karnofsky/Lansky verrà valutato allo Screening e alla Settimana 8.
    Valori di laboratorio per chimica clinica ed ematologia dallo Screening alla Settimana 8.
    Documentazione di tutti i farmaci concomitanti dallo Screening alla Settimana 8.
    Durante il follow-up della Settimana 15 saranno documentati solo terapia antivirale, immunosoppressione e farmaci concomitanti relativi a gravi eventi avversi, oltre alla chemioterapia.
    Le DLI non terapeutiche devono essere documentate come farmaci concomitanti (per la definizione si vedano i criteri di esclusione). Anche i trattamenti con cellule T specifiche-multivirus dopo la Settimana 8 saranno documentate come farmaci concomitanti
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 8 and Week 15
    Week 8 and Week 15
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA35
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 5
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 46
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 47
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 46
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    children
    bambini
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state54
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 149
    F.4.2.2In the whole clinical trial 149
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    local standard of care
    normale pratica clinica locale
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-08-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-03-25
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 02 00:12:00 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA